Catalyst Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Catalyst Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.1K	Buy	50 +11	+28%	+$3.32K	﹤0.01%	340
2026 Q1	$12.9K	Buy	+39	New	+$13.3K	﹤0.01%	346
2025 Q3	–	Sell	-453	Closed	-$148K	–	444
2025 Q2	$148K	Buy	+453	New	+$125K	﹤0.01%	276
2016 Q1	–	Sell	-1,000	Closed	-$94K	–	492
2015 Q4	$94K	Sell	1,000 -10,000	-91%	-$927K	0.01%	322
2015 Q3	$884K	Sell	11,000 -118,750	-92%	-$13.2M	0.12%	151
2015 Q2	$15.6M	Sell	129,750 -70,500	-35%	-$8.43M	1.81%	4
2015 Q1	$20.9M	Buy	+200,250	New	+$20.3M	2.4%	1

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Catalyst Capital Advisors's ALNY Position: Q2 2026 in Review

Catalyst Capital Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 28% in Q2 2026, buying an estimated $3.32K and bringing the position to 50 shares worth $15.1K. The position accounts for ﹤0.01% of the portfolio, ranked #340.

Catalyst Capital Advisors first reported a position in ALNY in Q1 2015 and has held it in 7 quarters since. The position peaked at $20.9M in Q1 2015. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Catalyst Capital Advisors held 50 shares of Alnylam Pharmaceuticals worth $15.1K as of Q2 2026.
Catalyst Capital Advisors bought 11 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $3.32K.
Alnylam Pharmaceuticals made up ﹤0.01% of Catalyst Capital Advisors's portfolio in Q2 2026, its #340 holding.
Catalyst Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2015 and has held it in 7 quarters since.
Catalyst Capital Advisors's Alnylam Pharmaceuticals position peaked at $20.9M in Q1 2015.
784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Catalyst Capital Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.